Bayer's Patent Cliff Defence Takes Shape as Sunharbo Clears the FDA

Bayer has secured US approval for its stroke-prevention drug Asundexian, marketed as Sunharbo — a green light the German group says makes it the world's first approved factor XIa inhibitor. The FDA cleared the treatment for adults at elevated risk of a repeat stroke, handing the company a fresh commercial lever just as it works to offset revenue lost to generic competition on its blockbuster anticoagulant Xarelto.

That handover from expiring patents to new growth engines is the yardstick by which the stock should be judged. Research milestones matter to investors only insofar as they broaden the earnings base and cushion the slide in older products, and Reuters has flagged Asundexian as a key growth driver for the pharma division precisely because it is meant to absorb the Xarelto patent-cliff losses.

The approval landed alongside a second regulatory win. China cleared Sevabertinib last week for first-line treatment of adults with advanced HER2-mutant non-small cell lung cancer — another addition to the renewal story, provided Bayer can convert it into extra business.

A split is off the table

Management has paired its innovation push with a firm structural stance. Chief executive Bill Anderson said on 3 November, according to media reports, that a break-up was not on the agenda and that Bayer would concentrate on innovation and debt reduction. Those two tasks together will determine whether product advances translate into economic value: innovation has to strengthen earnings power while also freeing up room to pay down borrowings.

Should investors sell immediately? Or is it worth buying Bayer?

The operating numbers offer some backing. In the third quarter of 2026, EBITDA before special items rose 6.9% to EUR 1.615 billion on revenue of EUR 10.053 billion, and Bayer lifted its full-year guidance roughly a week ago. Reuters reported that the company credited the upgrade to a better-than-expected performance in the pharma division.

Two brokers, two verdicts

Analysts read the same news very differently. Jefferies, which had anticipated the Asundexian approval, said it substantially reduces risk to Bayer's pharmaceutical pipeline — yet the broker stuck with a hold rating and a EUR 48.50 price target. Analyst Michael Leuchten called the approval expected and acknowledged the meaningful drop in pipeline risk, but kept his cautious stance intact.

Deutsche Bank moved the other way, lifting its target to EUR 65.00 from EUR 60.00 and reiterating a buy, citing higher profit estimates following the third quarter. The gap between the two positions is stark: at a closing price of EUR 57.22, the stock already trades above Jefferies' target, meaning anyone betting on further gains is taking a more generous view of the business than that house does.

Momentum cuts both ways

The bull case rests on improved operations and diminished development risk reinforcing each other. If Bayer commercialises its regulatory wins successfully, the pharma unit could keep justifying the raised guidance and lay the groundwork for further earnings gains — a scenario that would look more convincing if upcoming figures underpin the higher profit expectations.

Bayer at a turning point? This analysis reveals what investors need to know now.

The counterargument is that much of this is already in the price. The shares have climbed 55% since the start of the year, which leaves the stock increasingly dependent on Bayer confirming elevated expectations with hard operating results. Should earnings improve more slowly than optimists anticipate, the gap between business progress and market valuation could become a drag — particularly if the pharma division lends less support to profit forecasts than hoped.

The next anchor for that debate is the financial calendar: Bayer reports on its 2026 fiscal year on 24 February 2027. Until then, further operating updates and commentary on the commercial rollout of the approvals will decide whether lower pipeline risk turns into a durably stronger earnings base.

Ad

Bayer Stock: New Analysis - 11 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...